White Hat 2016_ After The Exit
Channel: AZ Bio
Date: 2016-10-24

After The Exit 

Moderated by 2016 White Hat Chair, Dirk Karsten Beth, Founder & CEO Hyalescent Ventures and Managing Director of US Operations for arivis , this panel features successful life science entrepreneurs who have reached "the exit" and will discuss what comes next.  Panelists include: 

John M. (Jock) Holliman, III  has served as Executive Chairman and Principal Executive Officer of Capstone Therapeutics since April 2006 and has served as a director of Capstone since September 1987 and as Chairman of the Board of Directors since August 1997. Since February 1993 he has been a general partner of entities which are the general partners of Valley Ventures, LP (formerly known as Arizona Growth Partners, LP), Valley Ventures II, LP, Valley Ventures III, LP, Valley Ventures III Annex, LP, all of which are venture capital funds that invest principally in life science companies.

Matt Likens led Ulthera from its early years  through its $600 M acquisition by Merz.  Mr. Likens joined Ulthera in July of 2006. He spent more than twenty years in domestic and international sales, marketing and general management roles at Baxter Healthcare Corporation, culminating in the positions of President of Baxter Biotech North America, then President of Baxter’s Renal Division in the U.S. In 2001, Mr. Likens joined GMP Companies, and was President of GMP Wireless Medicine, Inc.

David Mallery is a co-founder and President of the International Genomics Consortium (IGC), the Molecular Profiling Institute (now Caris Life Sciences), Viomics, and Paradigm Diagnostics.   David helped lead the financings and sale of the Molecular Profiling Institute, which returned 5x to the first institutional investors in 40 months.   David also served as the Principal advisor for VidaCare’s series A round, which was later sold to Teleflex for $265M.   IGC served as the founding Biospecimen Core Resource and Tissue Source Site for the NCI’s flagship The Cancer Genome Atlas project.   Paradigm recently consolidated as a for-profit at the Phoenix Biosciences Center and is in the process of fundraising – offering one of the most comprehensive, accurate, and rapid means of identifying the optimal targeted cancer therapeutics for patients.

David has a JD and MBA from the University of Colorado at Boulder and a BA in Human Biology and Art from Stanford University.  He is a member of YPO, the Council on Foreign Relations, and the District of Columbia Bar Association.